Drugs / Lodosyn
last change Oct 2022 re-read 2 minutes ago

Lodosyn

Developed for
multiple sclerosis
Investigated by
University of Miami

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) LODOSYN 1977-04-25 fda.gov

Trials 1 · a red edge is where a trial was stopped

today
US approved 1977
NCT04764383 · Ph 2
19761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04764383 Jan → Oct 2022 multiple sclerosis University of Miami Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Lodosyn ClinicalTrials.gov intervention name — accepted as the source's own label NCT04764383
Route Oral “taken PO” NCT04764383